Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Collagenase Clostridium Histolyticum

What is Collagenase Clostridium Histolyticum?

CAS No: 9001-12-1

Collagenase Clostridium Histolyticum is a pharmacologically active or chemically reactive compound used in pharmaceutical manufacturing as an active ingredient, synthetic intermediate, or process reagent, requiring toxicological characterisation to establish protective occupational exposure limits. Available data from in vitro and in vivo studies are evaluated in a weight-of-evidence assessment to identify the critical study, the most sensitive adverse effect endpoint, and the applicable NOAEL or LOAEL that serves as the point of departure for PDE calculation. Data gaps are addressed through read-across from structurally related compounds, (Q)SAR predictions, or application of TTC defaults where scientifically justified.

The critical toxicological endpoint driving the PDE for Collagenase Clostridium Histolyticum is selected through systematic comparison of all available study NOAELs across endpoint categories: general systemic toxicity, neurotoxicity, reproductive and developmental toxicity, genotoxicity, and carcinogenicity.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Collagenase Clostridium Histolyticum is a biologic consisting of collagenase enzymes produced by the bacterium Clostridium histolyticum. It is injected locally to break down collagen cords in Dupuytren contracture and plaques in Peyronie disease. As an enzyme protein, its local tissue effects, immunogenicity and sensitization potential are relevant to its assessment.

A PDE or ADE sets a health-based limit on daily exposure to Collagenase Clostridium Histolyticum from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Yes, health-based limits can be relevant for peptide and protein products such as Collagenase Clostridium Histolyticum. A PDE supports cross-contamination control in shared facilities, while an OEL or OEB helps protect workers handling the material. The assessment takes into account how the molecule acts, how it is absorbed and how it may be degraded, which can differ from small molecules.

Formulation, filling and equipment cleaning can each create opportunities for exposure to Collagenase Clostridium Histolyticum through aerosols, splashes or skin contact. The assessment considers the concentration and form of the material, the tasks performed and the controls in place, so that containment, personal protective equipment and cleaning procedures can be matched to the potential risk.

The PDE provides the health-based starting point for calculating the maximum allowable carryover of Collagenase Clostridium Histolyticum into the next product made in shared equipment. Cleaning limits derived from it, together with suitable analytical methods and sampling, help demonstrate that residues are reduced to a level not expected to pose a risk to patients.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Collagenase Clostridium Histolyticum in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

A Masuu Global report for Collagenase Clostridium Histolyticum presents the scientific rationale, the calculations behind each exposure limit, and clear recommendations for use in risk assessment. Reports are prepared by certified toxicologists and designed to be regulatory-ready, so quality, safety and regulatory teams can follow and review how each value was derived.

Potent pharmacological activity can drive the critical effect for Collagenase Clostridium Histolyticum, sometimes at doses well below those causing general toxicity. The assessment therefore looks at the mechanism of action, the lowest doses associated with pharmacological effects and the target population, and uses this information when selecting the point of departure and the adjustment factors.

Relevant evidence may include repeat-dose toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, and pharmacological activity where available. The critical effect is selected based on data quality and relevance. When data are limited, a documented, risk-based approach is used to address the gaps.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Collagenase Clostridium Histolyticum to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo